SAM
BMRN icon

Storebrand Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Storebrand Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Sell
208
-1,583
-88% -$86.7K ﹤0.01% 755
2026
Q1 		$101K Sell
1,791
-4,248
-70% -$248K ﹤0.01% 724
2025
Q4 		$359K Hold
6,039
– – ﹤0.01% 687
2025
Q3 		$327K Sell
6,039
-6,872
-53% -$393K ﹤0.01% 705
2025
Q2 		$710K Buy
12,911
+4,062
+46% +$239K ﹤0.01% 666
2025
Q1 		$626K Sell
8,849
-887
-9% -$59.7K ﹤0.01% 688
2024
Q4 		$640K Sell
9,736
-2,812
-22% -$188K ﹤0.01% 705
2024
Q3 		$882K Sell
12,548
-199
-2% -$16.6K ﹤0.01% 693
2024
Q2 		$1.05M Sell
12,747
-2,636
-17% -$219K ﹤0.01% 661
2024
Q1 		$1.34M Sell
15,383
-5,473
-26% -$490K ﹤0.01% 660
2023
Q4 		$2.01M Buy
20,856
+1,860
+10% +$165K 0.01% 637
2023
Q3 		$1.68M Sell
18,996
-6,859
-27% -$610K 0.01% 633
2023
Q2 		$2.24M Sell
25,855
-4,000
-13% -$376K 0.01% 612
2023
Q1 		$2.9M Sell
29,855
-3,052
-9% -$316K 0.01% 570
2022
Q4 		$3.41M Buy
32,907
+1,976
+6% +$186K 0.02% 528
2022
Q3 		$2.62M Sell
30,931
-5,907
-16% -$526K 0.02% 556
2022
Q2 		$3.05M Sell
36,838
-5,570
-13% -$443K 0.02% 548
2022
Q1 		$3.27M Sell
42,408
-535
-1% -$44.8K 0.02% 560
2021
Q4 		$3.79M Buy
42,943
+2,272
+6% +$187K 0.02% 550
2021
Q3 		$3.14M Sell
40,671
-1,735
-4% -$137K 0.02% 594
2021
Q2 		$3.54M Sell
42,406
-1,507
-3% -$119K 0.02% 592
2021
Q1 		$3.32M Sell
43,913
-1,522
-3% -$124K 0.02% 583
2020
Q4 		$3.98M Sell
45,435
-200
-0.4% -$15.9K 0.02% 538
2020
Q3 		$3.47M Buy
45,635
+4,698
+11% +$475K 0.02% 511
2020
Q2 		$5.05M Buy
40,937
+4,340
+12% +$431K 0.04% 391
2020
Q1 		$3.09M Buy
+36,597
New +$3.15M 0.03% 437

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Storebrand Asset Management's BMRN Position: Q2 2026 in Review

Storebrand Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 88% in Q2 2026, selling an estimated $86.7K and leaving 208 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Storebrand Asset Management first reported a position in BMRN in Q1 2020 and has held it in 26 quarters since. The position peaked at $5.05M in Q2 2020. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Storebrand Asset Management held 208 shares of BioMarin Pharmaceuticals worth $11.9K as of Q2 2026.
  • Storebrand Asset Management sold 1,583 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $86.7K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Storebrand Asset Management's portfolio in Q2 2026, its #755 holding.
  • Storebrand Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Storebrand Asset Management's BioMarin Pharmaceuticals position peaked at $5.05M in Q2 2020.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.